Geographic Accessibility and Availability of Radiotherapy in Ghana.
Journal
JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235
Informations de publication
Date de publication:
01 08 2022
01 08 2022
Historique:
entrez:
11
8
2022
pubmed:
12
8
2022
medline:
16
8
2022
Statut:
epublish
Résumé
Radiotherapy is critical for comprehensive cancer care, but there are large gaps in access. Within Ghana, data on radiotherapy availability and on the relationship between distance and access are unknown. To estimate the gaps in radiotherapy machine availability in Ghana and to describe the association between distance and access to care. This is a cross-sectional, population-based study of radiotherapy delivery in Ghana in 2020 and model-based analysis of radiotherapy demand and the radiotherapy utilization rate (RUR) using the Global Task Force on Radiotherapy for Cancer Control investment framework. Receipt of radiotherapy and the number of radiotherapy courses delivered. Geocoded location of patients receiving external beam radiotherapy (EBRT); median Euclidean distance from the district centroids to the nearest radiotherapy centers; proportion of population living within geographic buffer zones of 100, 150, and 200 km; additional capacity required for optimal utilization; and geographic accessibility after strategic location of a radiotherapy facility in an underserviced region. A total of 2883 patients underwent EBRT courses in 2020, with an actual RUR of 11%. Based on an optimal RUR of 48%, 11 524 patients had an indication for radiotherapy, indicating that only 23% of patients received treatment. An investment of 23 additional EBRT machines would be required to meet demand. The median Euclidean distance from the district centroids to the nearest radiotherapy facility was 110.6 km (range, 0.62-513.2 km). The proportion of the total population living within a radius of 100, 150 and 200 km of a radiotherapy facility was 47%, 61% and 70%, respectively. A new radiotherapy facility in the northern regional capital would reduce the median of Euclidean distance by 10% to 99.4 km (range, 0.62-267.7 km) and increase proportion of the total population living within a radius of 100, 150 and 200 km to 53%, 69% and 84%, respectively. The greatest benefit was seen in regions in the northern half of Ghana. In this cross-sectional study of geographic accessibility and availability of radiotherapy, Ghana had major national deficits of radiotherapy capacity, with significant geographic disparities among regions. Well-planned infrastructure scale-up that accounts for the population distribution could improve radiotherapy accessibility.
Identifiants
pubmed: 35951324
pii: 2795153
doi: 10.1001/jamanetworkopen.2022.26319
pmc: PMC9372791
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2226319Références
Med J Aust. 2011 Sep 19;195(6):350-4
pubmed: 21929501
J Glob Oncol. 2019 Oct;5:1-8
pubmed: 31634049
Radiother Oncol. 2019 Dec;141:48-55
pubmed: 31575428
Ann Surg Oncol. 2015 Apr;22(4):1095-101
pubmed: 25245129
Geospat Health. 2018 May 07;13(1):622
pubmed: 29772881
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Int J Cancer. 2021 Apr 5;:
pubmed: 33818764
PLoS One. 2019 Mar 21;14(3):e0213583
pubmed: 30897166
Radiother Oncol. 2014 Jul;112(1):140-4
pubmed: 24833561
Med Care. 1981 Feb;19(2):127-40
pubmed: 7206846
Clin Oncol (R Coll Radiol). 2017 Feb;29(2):84-92
pubmed: 27939337
Int J Equity Health. 2013 Mar 11;12:18
pubmed: 23496984
BMJ Support Palliat Care. 2022 Mar 15;:
pubmed: 35292512
Lancet Oncol. 2019 Jul;20(7):915-923
pubmed: 31151906
Lancet Oncol. 2015 Sep;16(10):1153-86
pubmed: 26419354
Radiother Oncol. 2020 May;146:1-8
pubmed: 32065874
Pan Afr Med J. 2020 Mar 25;35:90
pubmed: 32636988
BMC Public Health. 2012 Nov 16;12:991
pubmed: 23158554
Sci Data. 2017 Jan 31;4:170001
pubmed: 28140386
PLoS One. 2015 Feb 17;10(2):e0107042
pubmed: 25689585
J Clin Oncol. 2005 Oct 1;23(28):7074-80
pubmed: 16192590
Cancer. 2021 May 1;127(9):1432-1438
pubmed: 33370458
J Clin Oncol. 2015 Oct 1;33(28):3177-85
pubmed: 26304878
Lancet Oncol. 2022 Apr;23(4):531-539
pubmed: 35298907
Lancet Oncol. 2021 Sep;22(9):e391-e399
pubmed: 34478675